Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutated Lung Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02485652
What this trial is testing

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 162
Not applicableStudy completedNCT01167972
What this trial is testing

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 2,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07482605
What this trial is testing

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Who this might be right for
Lung Cancer (NSCLC)Malignant Pleural Effusions (Mpe)- Pleurodesis
Jiangmen Central Hospital 63
Testing effectiveness (Phase 2)Study completedNCT02044328
What this trial is testing

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 79
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Large-scale testing (Phase 3)UnknownNCT02125240
What this trial is testing

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Who this might be right for
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Betta Pharmaceuticals Co., Ltd. 124
Testing effectiveness (Phase 2)Study completedNCT02264210
What this trial is testing

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Who this might be right for
Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the Lung+4 more
Sun Yat-sen University 128
Testing effectiveness (Phase 2)Study completedNCT01116219
What this trial is testing

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

Who this might be right for
Lung Cancer
Swiss Cancer Institute 149
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06918782
What this trial is testing

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Who this might be right for
Lung Cancer (NSCLC)
The University of Hong Kong 47
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)UnknownNCT03486496
What this trial is testing

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Who this might be right for
Lung AdenocarcinomaEGFR Mutation
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Early research (Phase 1)Study completedNCT02926768
What this trial is testing

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungLung Diseases+1 more
Checkpoint Therapeutics, Inc. 136
Not applicableStudy completedNCT04370860
What this trial is testing

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Who this might be right for
EGFR Exon 19 MutationTumor Progression
National Taiwan University Hospital 1,000